title: Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial.
abstract: The polyphenol resveratrol is considered to exert many beneficial actions, such as antioxidant, anti-inflammatory, insulin-sensitizer and anticancer effects. Its benefits in patients with type 2 diabetes mellitus (T2DM) are controversial. Our aims were to determine whether resveratrol supplementation at two different dosages (500 and 40mg/day) for 6 months i) reduced the concentrations of C-reactive-protein (CRP) and ii) ameliorated the metabolic pattern of T2DM patients. In the present double-blind, randomized, placebo-controlled trial, 192 T2DM patients were randomized to receive resveratrol 500mg/day (Resv500arm), resveratrol 40mg/day (Resv40arm) or placebo for 6-months. At baseline and at the trial end, CRP values, anthropometric, metabolic and liver parameters were determined. No serious adverse event occurred. A dose-dependent, though not significant, CRP decrease of 5.6% (Resv40arm) and 15.9% (Resv500arm) was observed vs placebo. We failed to detect significant differences in weight, BMI, waist circumference, and values of arterial blood pressure, fasting glucose, glycated hemoglobin, insulin, C-peptide, free fatty acids, liver transaminases, uric acid, adiponectin, interleukin-6, in both the Resv500 and Resv40 arms vs placebo. Total cholesterol and triglycerides slightly increased in the Resv500arm. Subgroup analyses revealed that lower diabetes duration (in both Resv500 and Resv40arms), and, in the Resv500arm, younger age, aspirin use and being a smoker were associated with a significantly higher CRP reduction vs placebo. The supplementations with 40mg/day or 500mg/day resveratrol did neither reduce CRP concentrations, nor improve the metabolic pattern of T2DM patients.
authors: Department of Medical Sciences, University of Turin, Turin, Italy. Electronic address: simona.bo@unito.it.
authors: S
authors: S
authors: Bo
authors: Department of Medical Sciences, University of Turin, Turin, Italy.
authors: V
authors: V
authors: Ponzo
authors: Unit of Clinical Epidemiology, CPO, Città della Salute e della Scienza, Hospital of Turin, Turin, Italy.
authors: G
authors: G
authors: Ciccone
authors: Unit of Clinical Epidemiology, CPO, Città della Salute e della Scienza, Hospital of Turin, Turin, Italy.
authors: A
authors: A
authors: Evangelista
authors: Department of Medical Sciences, University of Turin, Turin, Italy.
authors: F
authors: F
authors: Saba
authors: Department of Medical Sciences, University of Turin, Turin, Italy.
authors: I
authors: I
authors: Goitre
authors: Department of Medical Sciences, University of Turin, Turin, Italy.
authors: M
authors: M
authors: Procopio
authors: Department of Medical Sciences, University of Turin, Turin, Italy.
authors: G F
authors: GF
authors: Pagano
authors: Department of Medical Sciences, University of Turin, Turin, Italy.
authors: M
authors: M
authors: Cassader
authors: Department of Medical Sciences, University of Turin, Turin, Italy.
authors: R
authors: R
authors: Gambino
mesh_terms: D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D019587:Dietary Supplements / Q000009:adverse effects; D004311:Double-Blind Method; D006304:Health Status; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D007558:Italy; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D018836:Inflammation Mediators; D013267:Stilbenes; D002097:C-Reactive Protein; D000077185:Resveratrol
keywords: C-reactive protein; Resveratrol; Resveratrol (PubChem CID: 445154); Type 2 diabetes mellitus